共 76 条
[1]
Skyler JS(2013)Primary and secondary prevention of type 1 diabetes Diabet Med 30 161-169
[2]
Greenbaum CJ(2008)Mixed-meal tolerance test versus glucagon stimulation test for the assessment of β-cell function in therapeutic trials in type 1 diabetes Diabetes Care 31 1966-1971
[3]
Mandrup-Poulsen T(2011)Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial Lancet 378 412-419
[4]
McGee PF(2009)Rituximab, B-lymphocyte depletion, and preservation of beta-cell function N Engl J Med 361 2143-2152
[5]
Orban T(2011)Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial Lancet 378 487-497
[6]
Bundy B(2009)New definition for the partial remission period in children and adolescents with type 1 diabetes Diabetes Care 32 1384-1390
[7]
Becker DJ(2014)Partial remission definition: validation based on the insulin dose-adjusted HbA1c (IDAA1C) in 129 Danish children with new-onset type 1 diabetes Pediatr Diabetes 15 469-476
[8]
Pescovitz MD(2008)A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1 Diabetes Care 31 528-533
[9]
Greenbaum CJ(2013)The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients Diabetes Care 36 2615-2620
[10]
Krause-Steinrauf H(2017)The influence of body mass index and age on C-peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trial-type 1 Pediatr Diabetes 19 403-409